Semnur Pharmaceuticals ( (SMNR) ) has issued an update.

On June 25, 2026, Semnur Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, with 100% of Series A preferred shares and approximately 87% of common shares represented virtually or by proxy as of the April 28, 2026 record date. Stockholders elected Jay Chun, M.D., Ph.D., as a Class I director to serve until the 2029 annual meeting, ratified Pipara & Co LLP as independent auditor for the fiscal year ending December 31, 2026, and approved both the 2025 Equity Incentive Plan and the 2025 Employee Stock Purchase Plan.

The director election and overwhelming approvals of the auditor appointment and equity-related plans reinforce the company’s existing governance structure and provide ongoing tools for employee and executive compensation. These outcomes support Semnur Pharmaceuticals’ ability to attract and retain talent and maintain financial reporting continuity, which are important for its operational stability and for aligning management and employee incentives with stockholder interests.